IN2012DN00971A - - Google Patents

Info

Publication number
IN2012DN00971A
IN2012DN00971A IN971DEN2012A IN2012DN00971A IN 2012DN00971 A IN2012DN00971 A IN 2012DN00971A IN 971DEN2012 A IN971DEN2012 A IN 971DEN2012A IN 2012DN00971 A IN2012DN00971 A IN 2012DN00971A
Authority
IN
India
Prior art keywords
adrenoceptor
activation
prevention
formula
treatment
Prior art date
Application number
Inventor
Scott D Edmondson
Lehua Chang
Gregori J Morriello
Christopher J Moyes
Nam Fung Kar
Dong-Ming Shen
Cheng Zhu
Neville J Anthony
Philip Jones
Graham F Smith
Mark E Scott
Christopher F Thompson
Joon Jung
Carolyn Cammarano
Dawn Marie Hoffman
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2012DN00971A publication Critical patent/IN2012DN00971A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ß3-adrenoceptor
IN971DEN2012 2009-08-27 2010-08-24 IN2012DN00971A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23748709P 2009-08-27 2009-08-27
PCT/US2010/046468 WO2011025774A1 (en) 2009-08-27 2010-08-24 Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
IN2012DN00971A true IN2012DN00971A (en) 2015-04-10

Family

ID=43628346

Family Applications (1)

Application Number Title Priority Date Filing Date
IN971DEN2012 IN2012DN00971A (en) 2009-08-27 2010-08-24

Country Status (10)

Country Link
US (1) US8604038B2 (en)
EP (1) EP2470012B1 (en)
JP (1) JP5671538B2 (en)
CN (1) CN102573471B (en)
AU (1) AU2010286694B2 (en)
BR (1) BR112012004333A2 (en)
CA (1) CA2770475C (en)
IN (1) IN2012DN00971A (en)
MX (1) MX2012002366A (en)
WO (1) WO2011025774A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2805427A1 (en) * 2010-07-23 2012-01-26 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
PE20131341A1 (en) 2010-08-03 2013-12-07 Altherx Inc COMBINATIONS OF BETA-3-ADRENERGIC RECEPTOR AGONISTS AND MUSCARINIC RECEPTOR ANTAGONISTS TO TREAT HYPERACTIVE BLADDER
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9486448B2 (en) 2013-10-03 2016-11-08 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (en) 2014-03-19 2017-02-22 无限药品股份有限公司 Heterocyclic compounds for the treatment of PI3K‑γ-mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2017007054A (en) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Compositions and methods of using modified release solabegron for lower urinary tract symptoms.
JP2018519292A (en) * 2015-07-01 2018-07-19 ファーマケア，インク． Lysyl oxidase like 2 inhibitor and use thereof
CN114230571B (en) 2015-09-14 2025-07-08 无限药品股份有限公司 Solid forms of isoquinolinones, methods of making, compositions comprising, and methods of using the same
CN108290824B (en) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 Sorabegron zwitterion and application thereof
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10408983B2 (en) 2016-08-16 2019-09-10 Moxtek, Inc. Durable, high performance wire grid polarizer having permeable junction between top protection layer
CN106831601A (en) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 A kind of synthetic method of 2 amino methylpyrimidine hydrochloride and its derivative
KR102736865B1 (en) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 Compounds that interact with the Ras superfamily for the treatment of cancer, inflammatory diseases, neurodevelopmental diseases and fibrotic diseases
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
EP3893892A4 (en) * 2018-12-12 2022-09-14 Rutgers, the State University of New Jersey ORGANIC COMPOUNDS
JP7407461B2 (en) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー Compounds that interact with the RAS superfamily for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
CN113816917B (en) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 Preparation method of wibeled intermediate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825227B (en) * 1981-07-22 1984-03-28 Syntex Inc Substituted pyrrolidine cardiovascular system regulators antihypertensives
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
PE20091825A1 (en) * 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
CA2719907A1 (en) * 2008-04-04 2009-10-08 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
US8354403B2 (en) * 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
WO2011025774A1 (en) 2011-03-03
CA2770475C (en) 2017-06-27
BR112012004333A2 (en) 2015-09-08
MX2012002366A (en) 2012-03-29
US20120225886A1 (en) 2012-09-06
AU2010286694B2 (en) 2013-09-12
JP5671538B2 (en) 2015-02-18
CN102573471B (en) 2014-11-26
EP2470012A1 (en) 2012-07-04
EP2470012B1 (en) 2014-11-05
CA2770475A1 (en) 2011-03-03
JP2013503167A (en) 2013-01-31
AU2010286694A1 (en) 2012-03-08
CN102573471A (en) 2012-07-11
US8604038B2 (en) 2013-12-10
EP2470012A4 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
IN2014CN04907A (en)
MX2012002366A (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists.
MA33803B1 (en) BENZODIAZEPINE BROMODOMAINE INHIBITOR
IN2012DN03883A (en)
PH12014500053A1 (en) Proteasome inhibitors
MY151246A (en) Benzofuranyl derivatives
MX2012000565A (en) Lupeol-type triterpene derivatives as antivirals.
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2018009945A (en) Novel compositions and methods for the treatment of immune related diseases.
GB201118656D0 (en) New compounds
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA107783C2 (en) Isoindoline compounds for use in treating cancer
IN2012MN02591A (en)
MX2012006730A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases.
JO3156B1 (en) fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as E.G. malaria
MX2012003644A (en) 2-pyridone compounds used as inhibitors of neutrophil elastase.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2012004780A (en) Akt inhibitors.
MX2011013577A (en) Compositions and methods for treating amyotrophic lateral sclerosis.
IN2012DN02471A (en)
MY164354A (en) Asymmetric ureas and medical uses thereof
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors